

EFFICACY OF A MULTI-INGREDIENT *CORIOLUS VERSICOLOR*-BASED VAGINAL GEL IN HIGH-RISK HPV INFECTED PATIENTS: RESULTS OF 6 DIFFERENT STUDIES

Authors:

Javier Cortes, Demian Dexeus, Santiago Palacios, Luis Serrano, Clara Gajino-Suarez, Elena Marín Ortíz, Anna Angela Criscuolo, Margarita Riera, Yann Gaslain

INTRODUCTION

To evaluate the consistency of the efficacy of a multi-ingredient *Coriolus versicolor*-based vaginal gel, on high-risk human papillomavirus (HR-HPV) clearance in 6 different studies.

METHODS:

Results from 4 independent observational studies (6 month-treatment period with *Coriolus versicolor*-based vaginal gel) were compared to results from a randomized, open, parallel, controlled trial (Paloma: NCT04002154) and an observational, multicenter, prospective, one-cohort study (PapilOBS: NCT04199260).

Vigo study: Prospective one-cohort. Secondary endpoint (SE), HPV clearance in 25 patients infected by HPV 16 and/or 18.

Coruña study: Retrospective one-cohort. Primary endpoint (PE), HPV clearance assessed in 57 medical patients' records.

Hospitalet study: Retrospective one-cohort. PE, Composite efficacy variable (patients with normal cytology and/or HPV clearance) in 91 HR-HPV patients.

Roma study: Retrospective controlled. PE, HR-HPV clearance in 183 patients.


Paloma trial: SE, HR-HPV clearance in 65 patients.

PapilOBS study: SE, HR-HPV clearance in 176 patients.

RESULTS:

In the Vigo study 48% of patients cleared HPV16/18, while in the Coruña study 58% of patients cleared HR-HPV. In the Hospitalet study 72.5% of patients normalized cytology and/or cleared HR-HPV. Furthermore, 67% of patients included in the Roma study cleared HR-HPV in the treated group vs 37.2% in the control group. In the Paloma trial, HR-HPV clearance reached 63% (treated group) vs 40% (control group). Finally, 57.4% HR-HPV clearance has been observed in the PapilOBS study.

RESULTS IN DIFFERENT STUDIES



CONCLUSIONS:

Coriolus versicolor-based vaginal gel has shown consistent efficacy rates across studies, with a 64% of HR-HPV clearance in average in 6 different studies involving 729 patients from which 597 represent HR-HPV cases.